Tag:

Onglyza

Latest Headlines

Latest Headlines

FDA puts AstraZeneca's diabetes med Onglyza on review for heart safety

AstraZeneca's diabetes drug Onglyza is under the FDA's microscope. The agency said it would review possible heart risks associated with the medication, which is one of the cornerstone products in the U.K.-based drugmaker's diabetes business.

The top Phase III R&D setbacks of 2013

The stats on Phase III success rates aren't good. About half end in failure--and that's after developers have had a chance to do some careful testing in humans. It's no wonder, then, that...

Onglyza fails outcomes trial in a $1B hit for Bristol-Myers, AstraZeneca

Bristol-Myers Squibb and AstraZeneca have lost out on a $1 billion boost for their diabetes partnership. Onglyza failed to beat placebo in a key outcomes trial, dashing hopes that new data would turbo-charge sales.

Another drug study flops at AstraZeneca as CEO braces for bumpy turnaround

In an interview with Reuters yesterday, CEO Pascal Soriot warned that turning around AstraZeneca is going to require a lengthy rebuilding effort.

Safety watchdog flags GLP-1 drugs for pancreatitis reports to FDA

A safety watchdog group has analyzed the FDA's adverse event data on the entire GLP-1 class of diabetes drugs, finding more reports of pancreatitis and pancreatic cancer for these drugs compared with older treatments.

Drugmakers beware, Costco now in pharmacy benefits

In the evolving drug payer world, pharmacy benefit managers (PBM) are commanding a bigger role. Now drug companies have a new and interesting PBM with which to contend--Costco.

Bristol, AstraZeneca chalk up EU approval for Forxiga after FDA rejection

Once again, European regulators have shown that they don't always see eye-to-eye with the their counterparts in the U.S. The European Commission welcomed a new diabetes drug from Bristol-Myers Squibb and AstraZeneca, dubbed Forxiga, just months after FDA rejected it on safety worries.

Generics drag AZ sales down by $1.35B

AstraZeneca's second-quarter results continue the generics-are-woe trend in Big Pharma. This time, it's the antipsychotic drug Seroquel doing most of the damage.

Bristol stays in hunt for Amylin

After Amylin reportedly declined BMS' recent buyout offer, Bristol isn't giving up on its plans to gobble up the diabetes drugmaker, The Wall Street Journal reported.

Bristol-Myers' Q4 shows growth in newer products

Bristol-Myers Squibb's ($BMY) earnings didn't reach the Wall Street goalposts, partly because of higher costs, some of them attributed to U.S. healthcare reforms. Sales of its flagship drug,...